Alder Bio (ALDR) on 9/16 with a $2B acquisition from Lundbeck that came at an 85% premium and included a CVR. Lundbeck highlighted the fact that eptinezumab could be the first intravenous CGRP drug to come to market. The takeover centers on a near-ap...